SPOTLIGHT: Investors expected to boost GSK, AZ


Credit Suisse lifted its share-price targets for GlaxoSmithKline, AstraZeneca, and Shire, saying it expects the pharma sector to be something of a port in a storm for investors worried about the economy. Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.